Nuformix
GBX0.2
4
+GBX0.02+11.73% Friday 12:04
Statistics
Day High
0.2
Day Low
0.18
52W High
0.44
52W Low
0.15
Volume
377,843
Avg. Volume
2,252,586
Mkt Cap
1.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
30JunExpected
Expected EPS
N/A
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NFX.LSE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap187.68B
GSK
GSK.LSE
Mkt Cap62.09B
Synairgen
SNG.LSE
Mkt Cap10.05M
HUTCHMED (China) Limited
HCM.LSE
Mkt Cap2.66B
Indivior
INDV.LSE
Mkt Cap1.06B
About
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Show more...
CEO
Dr. Daniel John Gooding
Employees
3
Country
GB
ISIN
GB00BYW79Y38
WKN
000A141LG